Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

Nicholas Zaorsky, Laura A. Doyle, Mark D. Hurwitz, Adam P. Dicker, Robert B. Den

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Low-dose rate brachytherapy (LDR-BT), involving implantation of radioactive seeds into the prostate, is an established monotherapy for most low-risk and select intermediate- and high-risk prostate cancer patients. High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT from a radiobiological and radiophysics perspective, to the patient himself, and in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in terms of biochemical control, patient survival, treatment toxicity and erectile preservation. However, there are still certain limitations that preclude recommending HDR-BT monotherapy for prostate cancer outside the setting of a clinical trial. HDR-BT monotherapy should be considered experimental at present.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Brachytherapy
Prostatic Neoplasms
Technology
Resource Allocation
Prostate
Seeds
Clinical Trials
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{e6c903cbb34a4f4eb8a3012506d796df,
title = "Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?",
abstract = "Low-dose rate brachytherapy (LDR-BT), involving implantation of radioactive seeds into the prostate, is an established monotherapy for most low-risk and select intermediate- and high-risk prostate cancer patients. High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT from a radiobiological and radiophysics perspective, to the patient himself, and in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in terms of biochemical control, patient survival, treatment toxicity and erectile preservation. However, there are still certain limitations that preclude recommending HDR-BT monotherapy for prostate cancer outside the setting of a clinical trial. HDR-BT monotherapy should be considered experimental at present.",
author = "Nicholas Zaorsky and Doyle, {Laura A.} and Hurwitz, {Mark D.} and Dicker, {Adam P.} and Den, {Robert B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14737140.2013.836303",
language = "English (US)",
volume = "14",
pages = "39--50",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? / Zaorsky, Nicholas; Doyle, Laura A.; Hurwitz, Mark D.; Dicker, Adam P.; Den, Robert B.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 1, 01.01.2014, p. 39-50.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

AU - Zaorsky, Nicholas

AU - Doyle, Laura A.

AU - Hurwitz, Mark D.

AU - Dicker, Adam P.

AU - Den, Robert B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Low-dose rate brachytherapy (LDR-BT), involving implantation of radioactive seeds into the prostate, is an established monotherapy for most low-risk and select intermediate- and high-risk prostate cancer patients. High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT from a radiobiological and radiophysics perspective, to the patient himself, and in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in terms of biochemical control, patient survival, treatment toxicity and erectile preservation. However, there are still certain limitations that preclude recommending HDR-BT monotherapy for prostate cancer outside the setting of a clinical trial. HDR-BT monotherapy should be considered experimental at present.

AB - Low-dose rate brachytherapy (LDR-BT), involving implantation of radioactive seeds into the prostate, is an established monotherapy for most low-risk and select intermediate- and high-risk prostate cancer patients. High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT from a radiobiological and radiophysics perspective, to the patient himself, and in terms of resource allocation. Studies of HDR-BT monotherapy have encouraging results in terms of biochemical control, patient survival, treatment toxicity and erectile preservation. However, there are still certain limitations that preclude recommending HDR-BT monotherapy for prostate cancer outside the setting of a clinical trial. HDR-BT monotherapy should be considered experimental at present.

UR - http://www.scopus.com/inward/record.url?scp=84893044597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893044597&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.836303

DO - 10.1586/14737140.2013.836303

M3 - Review article

VL - 14

SP - 39

EP - 50

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -